The 2022 Assisi Think Tank Meeting: white paper on optimising radiation therapy for breast cancer

dc.contributor.authorid0000-0002-3170-5826
dc.contributor.coauthorAristei, C.
dc.contributor.coauthorKaidar-Person, O.
dc.contributor.coauthorBoersma, L.
dc.contributor.coauthorLeonardi, M. C.
dc.contributor.coauthorOffersen, B.
dc.contributor.coauthorFranco, P.
dc.contributor.coauthorArenas, M.
dc.contributor.coauthorBourgier, C.
dc.contributor.coauthorPfeffer, R.
dc.contributor.coauthorKouloulias, V
dc.contributor.coauthorMeattini, I
dc.contributor.coauthorColes, C.
dc.contributor.coauthorLuis, A. Montero
dc.contributor.coauthorMasiello, V.
dc.contributor.coauthorPalumbo, I.
dc.contributor.coauthorMorganti, A. G.
dc.contributor.coauthorPerrucci, E.
dc.contributor.coauthorTombolini, V.
dc.contributor.coauthorKrengli, M.
dc.contributor.coauthorMarazzio, F.
dc.contributor.coauthorTrigo, L.
dc.contributor.coauthorBorghesi, S.
dc.contributor.coauthorCiabattoni, A.
dc.contributor.coauthorRatosa, I.
dc.contributor.coauthorValentini, V.
dc.contributor.coauthorPoortmans, P.
dc.contributor.departmentN/A
dc.contributor.kuauthorBölükbaşı, Yasemin
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid216814
dc.date.accessioned2025-01-19T10:29:29Z
dc.date.issued2023
dc.description.abstractThe present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. <70% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1-2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1-3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT-IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccesshybrid, Green Published
dc.description.publisherscopeInternational
dc.description.volume187
dc.identifier.doi10.1016/j.critrevonc.2023.104035
dc.identifier.eissn1879-0461
dc.identifier.issn1040-8428
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85160571618
dc.identifier.urihttps://doi.org/10.1016/j.critrevonc.2023.104035
dc.identifier.urihttps://hdl.handle.net/20.500.14288/25877
dc.identifier.wos1059240000001
dc.keywordsBreast cancer
dc.keywordsRadiation therapy
dc.keywordsCombined modality treatment
dc.keywordsImmunotherapy
dc.keywordsRe-irradiation in relapsed patients
dc.languageen
dc.publisherElsevier Science Inc
dc.sourceCritical Reviews in Oncology Hematology
dc.subjectOncology
dc.subjectHematology
dc.titleThe 2022 Assisi Think Tank Meeting: white paper on optimising radiation therapy for breast cancer
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR05568.pdf
Size:
1.62 MB
Format:
Adobe Portable Document Format